Aktien (@Aktien_Stammtisch) en getquin

Novo Nordisk Q3 24 Earnings: $NOVO B (-0,82 %)

- Sales DKK71.31B (est DKK72.44B)

- GLP-1 Sales DKK34.94B (est DKK39.24B)

- Ozempic Sales DKK29.80B (est DKK31.32B)

- Wegovy Sales DKK17.30B (est DKK15.63B)

- Sees FY OP Profit At Constant FX +21% To +27% (est +26.2%)

BMW Q3 24 Earnings: $BMW (+0,69 %)

- EBIT EU1.70B (est EU1.66B)

- Sales EU32.41B (est EU33.87B)

- EBIT Margin 2.3%, Est. 2.87%

- EBIT Margin 6% To 7%, Est. 6.94%

Henkel AG Q3 24 Earnings: $HEN (+0,25 %)

- Sales Eu5.49B, Est. Eu5.62B

- Organic Sales +3.3%, Est. +2.88%

- Still Sees FY Adj EBIT Margin 13.5% To 14.5%, Est. 14.2%

UniCredit Q3 24 Earnings: $NBLB-R-B

- Net Profit Eur 2.51 Bln (est Eur 2.27 Bln)

- Total Revenue Eur 6.14 Bln (est Eur 5.93 Bln)

- Net Interest Eur 3.56 Bln (est Eur 3.49 Bln)

- Net Commissions Eur 1.94 Bln (est Eur 1.95 Bln)

- Net Loans Writedown Eur 165 Mln (est Eur 187 Mln)

- Ups 2024 Net Revenue Guidance To Around Eur 24 Bln

- Ups 2024 Net Profit Guidance To Above Eur 9 Bln

- Provision For Distribution In 9m Of Eur 7.7 Bln, Or 100% Of Net Income

- Interim 2024 Cash Dividend Of About Eur 1.4 Bln

Commerzbank AG Q3 24 Earnings: $CBK (+0,59 %)

- Improves FY Outlook – Results After Nine Months Ahead Of Plan

- Outlook For Full Year: Net Result Target Of Around Eur 2.4bn Confirmed

- Remains Committed To Its Capital Return Plans And Planned Share Buybacks

- After First Nine Months Of Year, Commerzbank Confirms Its Profit Target For Full Year 2024

- Based On Strong Results Of Q3, Bank Is Raising Its Forecast For Net Interest Income From Around Eur 8.1bn To Around Eur 8.2bn For Full Year

- Net Commission Income Also Developed Better Than Planned: Bank Now Anticipates That Net Commission Income Will Exceed Previous Year's Figure By More Than 5%.

- Assumes Revenues Totalling Eur 10.9bn

- Anticipates A Cet1 Ratio Of Around 15%

Evonik Industries AG Q3 Earnings: $EVK (+0,22 %)

- Adjusted Ebitda Up 19% At Eur 577 Mln

- Group Sales Up By 2% At Eur 3.83 Bln

- Free Cash Flow Down To Eur 357 Mln From Eur 469 Mln Y-O-Y

- At Eur 701 Mln Total Free Cash Flow As Of September 30 Was Eur 415 Million Higher Than In 9-Month 2023

- Expects Total Savings From Cost Cut Initiatives Of About Eur 400 Mln

- Outlook 2024: Outlook For The Year Confirmed

Memo0606@Memo0606

2Semana

@Lugga2111_05 I thought novo would collapse more today after the figures
but they don't want to go down to €95 😞

•

Ver todas las 30 respuestas adicionales

Gomerdoc@Gomerdoc

1Semana

Novo Nordisk is not for market timers. Per annum rednite of the last 20 years: 22%. Looking at the last 5 years: 33%. Share price since 1991: From bottom left to top right. Dividend growth rate over the last 20 years: 15% per year. They are always at their highest price. These short-term small dips are no longer visible in the chart after 2 years: irrelevant. The risk of entering too late is much higher.

FelixTrade@FelixTrade

Bottomless as it was sold off again

••

Ver todas las 2 respuestas adicionales